Riley, Lantheus Holdings, Inc. (LNTH) maintains the “purchase” rating. Lower the PT

Lantheus Holdings, Inc. (NASDAQ:lnth) It is one of the best stocks of a Growth Stock Portfolio.

A lab coat pharmacist preparing drug-free nose spray for spraying.

Riley maintained its “buy” rating on June 24, 2025, reducing its LNTH price target from $122 to $109. The cuts follow the company’s profitability pressure despite top-line growth. On the one hand, revenues for the first quarter of 2025 increased by 0.8% year-on-year, while earnings per share (EPS) fell 9.5%, down $1.53 per share.

Meanwhile, Lantheus Holdings, Inc. (NASDAQ: LNTH) is making strategic moves amid margin pressure. That strategic move includes the acquisition of evergreen cerra and biomolecule imaging. In the future, the company plans to sell its technology from the Spect segment to make it shine. These initiatives highlight the company’s efforts to strengthen its pet-centric pipeline and strengthen its long-term position in radiation therapy.

Lantheus Holdings, Inc. (NASDAQ:LNTH) is a developer of radiopharmaceuticals and imaging solutions. Its portfolio consists of pet imaging agents such as Pylarify, ultrasound contrast definitions, and AI-driven imaging software.

Although we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater promotion potential and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.

Read next: Best Marketing Stocks to Buy Now and 10 Best Cybersecurity Stocks Investing Under $20.

Disclosure: None.